Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection.

Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, Sun Z, Xi C, Woytovich C, Farouk S, Huang W, Banu K, Gallon L, Magee CN, Najafian N, Samaniego M, Djamali A, Alexander SI, Rosales IA, Smith RN, Xiang J, Lerut E, Kuypers D, Naesens M, O'Connell PJ, Colvin R, Menon MC, Murphy B.

J Am Soc Nephrol. 2019 Jul 5. pii: ASN.2018111098. doi: 10.1681/ASN.2018111098. [Epub ahead of print]

PMID:
31278196
2.

Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection.

Zhang W, Yi Z, Wei C, Keung KL, Sun Z, Xi C, Woytovich C, Farouk S, Gallon L, Menon MC, Magee C, Najafian N, Samaniego MD, Djamali A, Alexander SI, Rosales IA, Smith RN, O'Connell PJ, Colvin R, Cravedi P, Murphy B.

JCI Insight. 2019 Jun 6;4(11). pii: 127543. doi: 10.1172/jci.insight.127543. eCollection 2019 Jun 6.

3.

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.

Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.

PLoS One. 2019 May 28;14(5):e0216300. doi: 10.1371/journal.pone.0216300. eCollection 2019.

4.

Recent advances of biosensors for hypertension and nephrology.

Park SH, Zhang Y, Rogers JA, Gallon L.

Curr Opin Nephrol Hypertens. 2019 Jul;28(4):390-396. doi: 10.1097/MNH.0000000000000517.

PMID:
31045660
5.

A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.

Mathew JM, H-Voss J, LeFever A, Konieczna I, Stratton C, He J, Huang X, Gallon L, Skaro A, Ansari MJ, Leventhal JR.

Sci Rep. 2018 May 9;8(1):7428. doi: 10.1038/s41598-018-25574-7.

6.

Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation.

West-Thielke P, Progar K, Campara M, Jasiak N, Gallon L, Tang I, Spaggiari M, Tzvetanov I, Benedetti E.

Transplant Proc. 2018 Jan - Feb;50(1):66-69. doi: 10.1016/j.transproceed.2017.12.015.

PMID:
29407333
7.

Cellular and functional biomarkers of clinical transplant tolerance.

Mathew JM, Ansari MJ, Gallon L, Leventhal JR.

Hum Immunol. 2018 May;79(5):322-333. doi: 10.1016/j.humimm.2018.01.009. Epub 2018 Jan 31. Review.

PMID:
29374560
8.

Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance.

Mathew JM, Voss JH, McEwen ST, Konieczna I, Chakraborty A, Huang X, He J, Gallon L, Kornbluth RS, Leventhal JR.

Sci Rep. 2018 Jan 18;8(1):1136. doi: 10.1038/s41598-018-19621-6.

9.

Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.

Gallon L, Mathew JM, Bontha SV, Dumur CI, Dalal P, Nadimpalli L, Maluf DG, Shetty AA, Ildstad ST, Leventhal JR, Mas VR.

J Am Soc Nephrol. 2018 Feb;29(2):423-433. doi: 10.1681/ASN.2017030348. Epub 2017 Nov 30.

10.

SuPAR and FSGS: is the jury still out?

Gallon L, Quaggin SE.

Nat Rev Nephrol. 2017 Sep;13(9):593. doi: 10.1038/nrneph.2017.109. Epub 2017 Jul 31. No abstract available.

PMID:
28757636
11.

KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX.

Transplantation. 2017 Aug;101(8S Suppl 1):S1-S109. doi: 10.1097/TP.0000000000001769.

12.

Summary of Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX.

Transplantation. 2017 Aug;101(8):1783-1792. doi: 10.1097/TP.0000000000001770. Review.

13.

Effects of DNA Methylation on Progression to Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Biopsies: A Multi-Omics Approach.

Bontha SV, Maluf DG, Archer KJ, Dumur CI, Dozmorov MG, King AL, Akalin E, Mueller TF, Gallon L, Mas VR.

Am J Transplant. 2017 Dec;17(12):3060-3075. doi: 10.1111/ajt.14372. Epub 2017 Jul 8.

14.

Glomerular disease: A suPAR kidney connection found in the bone marrow.

Gallon L, Quaggin SE.

Nat Rev Nephrol. 2017 May;13(5):263-264. doi: 10.1038/nrneph.2017.29. Epub 2017 Mar 13. No abstract available.

15.

A case of atypical hemolytic uremic syndrome in a second renal transplant.

Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L.

J Nephrol. 2018 Feb;31(1):165-172. doi: 10.1007/s40620-016-0373-7. Epub 2017 Feb 21.

PMID:
28224376
16.

The impact of coronary artery disease on outcomes after liver transplantation.

Skaro AI, Gallon LG, Lyuksemburg V, Jay CL, Zhao L, Ladner DP, VanWagner LB, De Wolf AM, Flaherty JD, Levitsky J, Abecassis MM, Gheorghiade M.

J Cardiovasc Med (Hagerstown). 2016 Dec;17(12):875-885.

PMID:
25517876
17.

APOL1-Associated End-Stage Renal Disease in a Living Kidney Transplant Donor.

Zwang NA, Shetty A, Sustento-Reodica N, Gordon EJ, Leventhal J, Gallon L, Friedewald JJ.

Am J Transplant. 2016 Dec;16(12):3568-3572. doi: 10.1111/ajt.14035. Epub 2016 Oct 6.

18.

Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.

O'Connell PJ, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, Luan Y, Rosales IA, Ge Y, Losic B, Xi C, Woytovich C, Keung KL, Wei C, Greene I, Overbey J, Bagiella E, Najafian N, Samaniego M, Djamali A, Alexander SI, Nankivell BJ, Chapman JR, Smith RN, Colvin R, Murphy B.

Lancet. 2016 Sep 3;388(10048):983-93. doi: 10.1016/S0140-6736(16)30826-1. Epub 2016 Jul 22.

19.

Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.

Levitsky J, Miller J, Huang X, Gallon L, Leventhal JR, Mathew JM.

PLoS One. 2016 Jun 8;11(6):e0156535. doi: 10.1371/journal.pone.0156535. eCollection 2016.

20.

Experimental protocol of a randomized controlled clinical trial investigating the effects of personalized exercise rehabilitation on kidney transplant recipients' outcomes.

Kastelz A, Tzvetanov IG, Fernhall B, Shetty A, Gallon L, West-Thielke P, Hachaj G, Grazman M, Benedetti E.

Contemp Clin Trials. 2015 Nov;45(Pt B):170-176. doi: 10.1016/j.cct.2015.10.002. Epub 2015 Oct 22.

PMID:
26475662
21.

Prolonged norovirus infection after pancreas transplantation: a case report and review of chronic norovirus.

Echenique IA, Stosor V, Gallon L, Kaufman D, Qi C, Zembower TR.

Transpl Infect Dis. 2016 Feb;18(1):98-104. doi: 10.1111/tid.12472. Epub 2015 Nov 25. Review.

PMID:
26460906
22.

Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers.

Leventhal JR, Mathew JM, Salomon DR, Kurian SM, Friedewald JJ, Gallon L, Konieczna I, Tambur AR, Charette J, Levitsky J, Jie C, Kanwar YS, Abecassis MM, Miller J.

Am J Transplant. 2016 Jan;16(1):221-34. doi: 10.1111/ajt.13416. Epub 2015 Jul 30.

23.

Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.

Traitanon O, Mathew JM, La Monica G, Xu L, Mas V, Gallon L.

PLoS One. 2015 Jun 18;10(6):e0129658. doi: 10.1371/journal.pone.0129658. eCollection 2015.

24.

Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.

Gallon L, Traitanon O, Yu Y, Shi B, Leventhal JR, Miller J, Mas V, L X, Mathew JM.

Transplantation. 2015 Sep;99(9):1774-84. doi: 10.1097/TP.0000000000000717.

PMID:
25905982
25.

Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants.

Leventhal JR, Elliott MJ, Yolcu ES, Bozulic LD, Tollerud DJ, Mathew JM, Konieczna I, Ison MG, Galvin J, Mehta J, Badder MD, Abecassis MM, Miller J, Gallon L, Ildstad ST.

Transplantation. 2015 Feb;99(2):288-98. doi: 10.1097/TP.0000000000000605.

PMID:
25594553
26.

Chimerism and tolerance induction in kidney transplantation.

Traitanon O, Gallon L.

Nephron. 2015;129(1):34-8. doi: 10.1159/000369311. Epub 2014 Dec 17. Review.

27.

A novel and personalized rehabilitation program for obese kidney transplant recipients.

Tzvetanov I, West-Thielke P, D'Amico G, Johnsen M, Ladik A, Hachaj G, Grazman M, Heller RU, Fernhall B, Daviglus ML, Solaro RJ, Oberholzer J, Gallon L, Benedetti E.

Transplant Proc. 2014 Dec;46(10):3431-7. doi: 10.1016/j.transproceed.2014.05.085.

PMID:
25498067
28.

Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis.

Menon MC, Chuang PY, Li Z, Wei C, Zhang W, Luan Y, Yi Z, Xiong H, Woytovich C, Greene I, Overbey J, Rosales I, Bagiella E, Chen R, Ma M, Li L, Ding W, Djamali A, Saminego M, O'Connell PJ, Gallon L, Colvin R, Schroppel B, He JC, Murphy B.

J Clin Invest. 2015 Jan;125(1):208-21. doi: 10.1172/JCI76902. Epub 2014 Dec 1.

29.

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.

Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekberg H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA.

BMJ. 2014 Nov 24;349:g6679. doi: 10.1136/bmj.g6679. Review. Erratum in: BMJ. 2014;349:g7543.

30.

Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus.

Gallon L, Traitanon O, Sustento-Reodica N, Leventhal J, Ansari MJ, Gehrau RC, Ariyamuthu V, De Serres SA, Alvarado A, Chhabra D, Mathew JM, Najafian N, Mas V.

Kidney Int. 2015 Apr;87(4):828-38. doi: 10.1038/ki.2014.350. Epub 2014 Oct 29.

31.

Incidence and impact of rejection following simultaneous liver-kidney transplantation.

Nilles KM, Krupp J, Lapin B, Sustento-Reodica N, Gallon L, Levitsky J.

J Hepatol. 2015 Feb;62(2):340-5. doi: 10.1016/j.jhep.2014.08.037. Epub 2014 Sep 6.

PMID:
25195555
32.

Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies.

Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI.

Transplantation. 2015 Feb;99(2):424-30. doi: 10.1097/TP.0000000000000270.

33.

Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Chang Y, Gallon L, Jay C, Shetty K, Ho B, Levitsky J, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI.

Liver Transpl. 2014 Sep;20(9):1034-44. doi: 10.1002/lt.23899.

34.

Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction.

Maluf DG, Dumur CI, Suh JL, Lee JK, Cathro EP, King AL, Gallon L, Brayman KL, Mas VR.

Am J Transplant. 2014 May;14(5):1152-1163. doi: 10.1111/ajt.12696. Epub 2014 Apr 2.

35.

The urine microRNA profile may help monitor post-transplant renal graft function.

Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, Lee JK, Gehrau RC, Brayman KL, Gallon L, Mas VR.

Kidney Int. 2014 Feb;85(2):439-49. doi: 10.1038/ki.2013.338. Epub 2013 Sep 11.

36.

Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.

Chhabra D, Alvarado A, Dalal P, Leventhal J, Wang C, Sustento-Reodica N, Najafian N, Skaro A, Levitsky J, Mas V, Gallon L.

Am J Transplant. 2013 Nov;13(11):2902-11. doi: 10.1111/ajt.12437. Epub 2013 Sep 5.

37.

Genomic biomarkers correlate with HLA-identical renal transplant tolerance.

Leventhal JR, Mathew JM, Salomon DR, Kurian SM, Suthanthiran M, Tambur A, Friedewald J, Gallon L, Charette J, Levitsky J, Kanwar Y, Abecassis M, Miller J.

J Am Soc Nephrol. 2013 Sep;24(9):1376-85. doi: 10.1681/ASN.2013010068. Epub 2013 Jun 20.

38.

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Bock ME, Price HE, Gallon L, Langman CB.

Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.

39.

HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.

Leventhal JR, Mathew JM, Ildstad S, Salomon DR, Kurian SM, Suthanthiran M, Tambur A, Friedewald J, Gallon L, Charette J, Levitsky J, Kanwar Y, Abecassis M, Miller J.

Clin Transpl. 2013:145-56.

PMID:
25095503
40.

Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome.

Leventhal J, Abecassis M, Miller J, Gallon L, Tollerud D, Elliott MJ, Bozulic LD, Houston C, Sustento-Reodica N, Ildstad ST.

Transplantation. 2013 Jan 15;95(1):169-76. doi: 10.1097/TP.0b013e3182782fc1.

41.

Outcomes and native renal recovery following simultaneous liver-kidney transplantation.

Levitsky J, Baker T, Ahya SN, Levin ML, Friedewald J, Gallon L, Ho B, Skaro A, Krupp J, Wang E, Spies SM, Salomon DR, Abecassis MM.

Am J Transplant. 2012 Nov;12(11):2949-57. doi: 10.1111/j.1600-6143.2012.04182.x. Epub 2012 Jul 3.

42.

Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.

Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A.

N Engl J Med. 2012 Apr 26;366(17):1648-9. doi: 10.1056/NEJMc1202500. No abstract available.

PMID:
22533598
43.

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.

Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST.

Sci Transl Med. 2012 Mar 7;4(124):124ra28. doi: 10.1126/scitranslmed.3003509.

44.

Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury.

Cassis P, Gallon L, Benigni A, Mister M, Pezzotta A, Solini S, Gagliardini E, Cugini D, Abbate M, Aiello S, Rocchetta F, Scudeletti P, Perico N, Noris M, Remuzzi G.

Kidney Int. 2012 May;81(9):903-18. doi: 10.1038/ki.2011.473. Epub 2012 Feb 8.

45.

Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.

Clin J Am Soc Nephrol. 2012 Mar;7(3):504-12. doi: 10.2215/CJN.06940711. Epub 2012 Jan 26.

46.

Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.

Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, Herrera N, Al-Saden P, Gallon L, Abdul-Nabi A, Yang GY, Kurian SM, Salomon DR, Miller J.

Hepatology. 2013 Jan;57(1):239-48. doi: 10.1002/hep.25579. Epub 2012 Jul 17.

47.

T-cell-depleting agents in kidney transplantation: is there a place for alemtuzumab?

Gallon L, Chhabra D, Skaro AI.

Am J Kidney Dis. 2012 Jan;59(1):15-8. doi: 10.1053/j.ajkd.2011.09.005. Epub 2011 Oct 8. No abstract available.

PMID:
21983588
48.

Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation.

Levitsky J, Salomon DR, Abecassis M, Langfelder P, Horvath S, Friedewald J, Wang E, Kurian SM, Mondala T, Gil S, McDade R, Ballard K, Gallon L.

Am J Transplant. 2011 Sep;11(9):1972-8. doi: 10.1111/j.1600-6143.2011.03669.x. Epub 2011 Jul 27.

49.

Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats.

Cassis P, Azzollini N, Solini S, Mister M, Aiello S, Cugini D, Scudeletti P, Gagliardini E, Abbate M, Gallon L, Remuzzi G, Noris M.

Transplantation. 2011 Aug 15;92(3):271-9. doi: 10.1097/TP.0b013e3182241106.

PMID:
21705971
50.

Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.

Levitsky J, Gallon L, Miller J, Tambur AR, Leventhal J, Flaa C, Huang X, Sarraj B, Wang E, Mathew JM.

Transplantation. 2011 Jan 27;91(2):199-206. doi: 10.1097/TP.0b013e318200e97.

Supplemental Content

Loading ...
Support Center